Barry S Rosenstein

List of Publications by Year
in descending order

93	5,327	71004	100535
papers	citations	43 h-index	70 g-index

97	97	97	6473
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.3	10
2	Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy. Brachytherapy, 2022, 21, 460-467.	0.2	2
3	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	2.0	14
4	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer, 2022, 166, 228-241.	0.9	5
5	Ocular complications with the use of radium-223: a case series. Radiation Oncology, 2022, 17, 97.	1.2	1
6	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
7	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	2.0	16
8	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	5.8	40
9	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.3	11
10	A first radiotherapy application of functional bulboclitoris anatomy, a novel female sexual organ-at-risk, and organ-sparing feasibility study. British Journal of Radiology, 2021, 94, 20201139.	1.0	4
11	A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy. Computers in Biology and Medicine, 2021, 135, 104624.	3.9	3
12	ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1373-1382.	0.4	12
13	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	3.0	71
14	Response to Letter to the Editor: Regarding â€œTeaching Radiation and Cancer Biology to Radiation Oncology Residents: A 40-Year Perspectiveâ€• Practical Radiation Oncology, 2020, 10, 70-71.	1.1	1
15	Use of genomics to balance cure and complications. Nature Reviews Clinical Oncology, 2020, 17, 9-10.	12.5	0
16	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	1.3	15
17	I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes. Brachytherapy, 2020, 19, 567-573.	0.2	1
18	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	1.7	16

#	Article	IF	Citations
19	Genomics models in radiotherapy: From mechanistic to machine learning. Medical Physics, 2020, 47, e203-e217.	1.6	17
20	Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 897-904.	0.6	1
21	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	1.3	1
22	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.4	69
23	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
24	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.3	53
25	Delays in radiation therapy as a result of insurance peer-to-peer prior authorizations among lung cancer patients. Journal of Radiation Oncology, 2019, 8, 389-393.	0.7	1
26	Teaching Radiation and Cancer Biology to Radiation Oncology Residents: AÂ40-Year Perspective. Practical Radiation Oncology, 2019, 9, 392-394.	1.1	2
27	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
28	Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 128-135.	0.4	73
29	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	5.8	43
30	Genomics, bio specimens, and other biological data: Current status and future directions. Medical Physics, 2018, 45, e829-e833.	1.6	3
31	Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. Medical Physics, 2018, 45, e811-e819.	1.6	17
32	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in Oncology, 2018, 8, 228.	1.3	54
33	How will radiogenomics improve breast cancer management?. Breast Cancer Management, 2018, 7, BMT03.	0.2	0
34	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
35	Radiation biology and oncology in the genomic era. British Journal of Radiology, 2018, 91, 20170949.	1.0	25
36	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88

#	Article	IF	Citations
37	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. International Journal of Particle Therapy, 2018, 5, 103-113.	0.9	6
38	Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes. Scientific Reports, 2017, 7, 43381.	1.6	35
39	Preconditioned Random Forest Regression. , 2017, , .		0
40	Radiogenomics and radiotherapy response modeling. Physics in Medicine and Biology, 2017, 62, R179-R206.	1.6	43
41	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	1.3	36
42	Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity. Seminars in Radiation Oncology, 2017, 27, 300-309.	1.0	46
43	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.3	15
44	Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. Cancer Letters, 2016, 382, 95-109.	3.2	68
45	Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. International Journal of Radiation Oncology Biology Physics, 2016, 95, 571-578.	0.4	19
46	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British Journal of Cancer, 2016, 114, 1165-1174.	2.9	17
47	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	2.7	69
48	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.3	98
49	Overview of the American Society for Radiation Oncologyâ€“National Institutes of Healthâ€“American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. International Journal of Radiation Oncology Biology Physics, 2016, 95, 873-879.	0.4	27
50	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.4	25
51	The REQUITE Project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors.. Journal of Clinical Oncology, 2016, 34, 85-85.	0.8	0
52	The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphismâ^'Based Models: A Step Toward Prevention. Seminars in Radiation Oncology, 2015, 25, 281-291.	1.0	52
53	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1084-1092.	0.4	64
54	Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncology, 2014, 10, 2391-2406.	1.1	63

#	Article	IF	Citations
55	STROGAR â€“ STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiotherapy and Oncology, 2014, 110, 182-188.	0.3	59
56	Radiogenomics: Using Genetics to Identify Cancer Patients at Risk for Development of Adverse Effects Following Radiotherapy. Cancer Discovery, 2014, 4, 155-165.	7.7	103
57	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nature Genetics, 2014, 46, 891-894.	9.4	114
58	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.4	99
59	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.3	128
60	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.. Journal of Clinical Oncology, 2014, 32, 276-276.	0.8	0
61	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms After Radiotherapy for Prostate Cancer. Journal of Urology, 2013, 190, 102-108.	0.2	55
62	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, e21-e28.	0.4	59
63	Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiotherapy and Oncology, 2013, 107, 372-376.	0.3	70
64	Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy. Frontiers in Oncology, 2012, 2, 44.	1.3	21
65	Predicting toxicity from radiation therapyâ€”It's genetic, right?. Cancer, 2012, 118, 3450-3454.	2.0	10
66	Genome-Wide Association Studies and Prediction of Normal Tissue Toxicity. Seminars in Radiation Oncology, 2012, 22, 91-99.	1.0	23
67	Influence of Pretreatment and Treatment Factors on Intermediate to Long-Term Outcome After Prostate Brachytherapy. Journal of Urology, 2011, 185, 495-500.	0.2	64
68	Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics, 2011, 12, 267-275.	0.6	34
69	Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Doseâ€“Volume Effects. International Journal of Radiation Oncology Biology Physics, 2010, 76, S145-S150.	0.4	69
70	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.4	118
71	Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms (SNPs) Associated With the Development of Erectile Dysfunction in African-American Men After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1292-1300.	0.4	143
72	Establishment of a radiogenomics consortium. Radiotherapy and Oncology, 2010, 94, 117-118.	0.3	56

#	Article	IF	Citations
73	American Society for Radiation Oncology (ASTRO) Survey of Radiation Biology Educators in U.S. and Canadian Radiation Oncology Residency Programs. International Journal of Radiation Oncology Biology Physics, 2009, 75, 896-905.	0.4	19
74	TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 752-759.	0.4	64
75	Feasibility of Accelerated Whole-Breast Radiation in the Treatment of Patients with Ductal Carcinoma In Situ of the Breast. Clinical Breast Cancer, 2008, 8, 269-274.	1.1	19
76	Association of Single Nucleotide Polymorphisms inSOD2, XRCC1andXRCC3with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer. Radiation Research, 2008, 170, 49-59.	0.7	81
77	Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy. Clinical Cancer Research, 2008, 14, 6284-6288.	3.2	136
78	Phase I-II Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue. Journal of Clinical Oncology, 2007, 25, 2236-2242.	0.8	154
79	A Genetically Determined Doseâ€“Volume Histogram Predicts for Rectal Bleeding among Patients Treated With Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1410-1416.	0.4	54
80	Possession of ATM Sequence Variants as Predictor for Late NormalÂTissue Responses in Breast Cancer Patients Treated WithÂRadiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 677-684.	0.4	79
81	Accelerated Intensity-Modulated Radiotherapy to Breast in Prone Position: Dosimetric Results. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1251-1259.	0.4	47
82	Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 527-533.	0.4	221
83	ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 776-783.	0.4	95
84	ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 196-202.	0.4	88
85	In response to Dr. Morgan. International Journal of Radiation Oncology Biology Physics, 2005, 62, 943-944.	0.4	0
86	Prone accelerated partial breast irradiation after breast-conserving surgery: Preliminary clinical results and doseâ€“volume histogram analysis. International Journal of Radiation Oncology Biology Physics, 2004, 60, 493-504.	0.4	225
87	Biologic comparison of partial breast irradiation protocols. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1393-1404.	0.4	90
88	T1 Stage Breast Cancer: Adjuvant Hypofractionated Conformal Radiation Therapy to Tumor Bed in Selected Postmenopausal Breast Cancer Patientsâ€”Pilot Feasibility Study. Radiology, 2002, 222, 171-178.	3.6	109
89	Toward a Consensus on Radiobiology Teaching to Radiation Oncology Residents. Radiation Research, 2002, 157, 599-606.	0.7	12
90	Toward a national consensus: teaching radiobiology to radiation oncology residents. International Journal of Radiation Oncology Biology Physics, 2002, 54, 861-872.	0.4	12

#	Article	IF	Citations
91	ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. International Journal of Radiation Oncology Biology Physics, 2002, 52, 606-613.	0.4	153
92	Screening breast cancer patients forATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environmental and Molecular Mutagenesis, 2001, 38, 200-208.	0.9	24
93	ATM heterozygosity and breast cancer: screening of 37 breast cancer patients for ATM mutations using a non-isotopic RNase cleavage-based assay. Breast Cancer Research and Treatment, 2000, 61, 79-85.	1.1	11